BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2426131)

  • 1. Potential drugs for elimination of acute lymphatic leukemia cells from autologous bone marrow.
    Blaauw A; Spitzer G; Dicke K; Drewinko B; Vellekoop L; Zander A
    Exp Hematol; 1986 Aug; 14(7):683-8. PubMed ID: 2426131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of drugs for elimination of leukemic cells from the bone marrow of patients with acute leukemia.
    Auber ML; Horwitz LJ; Blaauw A; Khorana S; Tucker S; Woods T; Warmuth M; Dicke KA; McCredie KB; Spitzer G
    Blood; 1988 Jan; 71(1):166-72. PubMed ID: 2446678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update.
    Peters RH; Brandon CS; Avila LA; Gale GR; Stuart RK
    Prog Clin Biol Res; 1990; 333():57-68. PubMed ID: 2309001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis.
    Chang TT; Gulati SC; Chou TC; Vega R; Gandola L; Ibrahim SM; Yopp J; Colvin M; Clarkson BD
    Cancer Res; 1985 Jun; 45(6):2434-9. PubMed ID: 3857119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of recombinant human tumor necrosis factor on highly enriched hematopoietic progenitor cell populations from normal human bone marrow and peripheral blood and bone marrow from patients with chronic myeloid leukemia.
    Wisniewski D; Strife A; Atzpodien J; Clarkson BD
    Cancer Res; 1987 Sep; 47(18):4788-94. PubMed ID: 3040231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro sensitivity of human hematopoietic progenitor cells to 4-hydroperoxycyclophosphamide.
    Ratajczak MZ; Ratajczak J; Kuczynski W; Light B; Lusk EJ; Gewirtz AM
    Exp Hematol; 1993 Dec; 21(13):1663-7. PubMed ID: 8243568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential cytotoxic activity of chemotherapy agents on colony-forming cells from human tumors and normal bone marrow in vitro.
    Ajani JA; Blaauw AA; Spitzer G; Baker FL; Tomasovic B; Umbach G; Thielvoldt D; Zander AR; Dicke KA
    Exp Hematol; 1985; 13 Suppl 16():95-100. PubMed ID: 2580731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of retinoic acid on the clonal growth of childhood myeloid and lymphoid leukemias: a pediatric oncology group study.
    Findley HW; Steuber CP; Ruymann FB; Culbert S; Ragab AH
    Exp Hematol; 1984 Nov; 12(10):768-73. PubMed ID: 6334611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro evaluation of combination drug purging for autologous bone marrow transplantation.
    Jones RJ; Miller CB; Zehnbauer BA; Rowley SD; Colvin OM; Sensenbrenner LL
    Bone Marrow Transplant; 1990 May; 5(5):301-7. PubMed ID: 2350626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
    Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
    Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of late and early hematopoietic progenitor/stem cell sensitivity to mafosfamide.
    Douay L; Giarratana MC; Labopin M; Bardinet D; Bouchet S; Gorin NC
    Bone Marrow Transplant; 1995 May; 15(5):769-75. PubMed ID: 7670404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological study for in vitro use of monoclonal antibody for autologous bone marrow transplantation in null cell-type acute lymphocytic leukemia.
    Sao H; Morishima Y; Ueda R; Yoshikawa S; Kodera Y; Ohno R; Takahashi T
    Jpn J Cancer Res; 1985 Dec; 76(12):1212-21. PubMed ID: 3937833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suitability of a new stable acetal analogue of aldoifosphamide for purging leukemic cells from human bone marrow.
    Andersson BS; Wang YQ; McCredie KB; Farquhar D
    Leukemia; 1990 Jun; 4(6):435-40. PubMed ID: 2359343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative regimens for the ex vivo chemopurification of B cell lymphoma-contaminated marrow.
    Gulati SC; Atzpodien J; Langleben A; Shimazaki C; Jain K; Yopp J; Ng RP; Colvin OM; Clarkson BD
    Acta Haematol; 1988; 80(2):65-70. PubMed ID: 2458665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of IL-1 on human hematopoietic progenitor cells treated in vitro with 4-hydroperoxycyclophosphamide.
    Moreb J; Zucali JR; Gross MA; Weiner RS
    J Immunol; 1989 Mar; 142(6):1937-42. PubMed ID: 2784143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Difference in kinetics of hematopoietic reconstitution between ALL and ANLL after autologous bone marrow transplantation with marrow treated in vitro with mafosfamide (ASTA Z 7557).
    Douay L; Laporte JP; Mary JY; Lopez M; Lemonnier MP; Stachowiak J; Benitez O; Deloux J; Najman A; Salmon C
    Bone Marrow Transplant; 1987 Jun; 2(1):33-43. PubMed ID: 3332155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a combined treatment with ASTA-Z 7654 and VP16-213 in vitro in eradicating clonogenic tumor cells from human bone marrow.
    De Fabritiis P; Pulsoni A; Sandrelli A; Simone F; Amadori S; Meloni G; Mandelli F
    Bone Marrow Transplant; 1987 Oct; 2(3):287-98. PubMed ID: 3502785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
    Janikova A; Koristek Z; Vinklarkova J; Pavlik T; Sticha M; Navratil M; Kral Z; Vasova I; Mayer J
    Exp Hematol; 2009 Nov; 37(11):1266-73. PubMed ID: 19654036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of the ability to purge tumor from murine bone marrow using clonogenic assays.
    Jones RJ; Colvin OM; Sensenbrenner LL
    Cancer Res; 1988 Jun; 48(12):3394-7. PubMed ID: 3285994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.